PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
INVZ vs. DNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between INVZ and DNA is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.4

Performance

INVZ vs. DNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Innoviz Technologies Ltd. (INVZ) and Ginkgo Bioworks Holdings, Inc. (DNA). The values are adjusted to include any dividend payments, if applicable.

-50.00%0.00%50.00%100.00%150.00%AugustSeptemberOctoberNovemberDecember2025
93.47%
-3.25%
INVZ
DNA

Key characteristics

Sharpe Ratio

INVZ:

-0.09

DNA:

-0.72

Sortino Ratio

INVZ:

0.67

DNA:

-1.16

Omega Ratio

INVZ:

1.07

DNA:

0.87

Calmar Ratio

INVZ:

-0.10

DNA:

-0.77

Martin Ratio

INVZ:

-0.19

DNA:

-1.11

Ulcer Index

INVZ:

48.79%

DNA:

69.11%

Daily Std Dev

INVZ:

100.03%

DNA:

105.52%

Max Drawdown

INVZ:

-96.06%

DNA:

-99.10%

Current Drawdown

INVZ:

-86.88%

DNA:

-98.19%

Fundamentals

Market Cap

INVZ:

$290.13M

DNA:

$622.50M

EPS

INVZ:

-$0.60

DNA:

-$12.89

Total Revenue (TTM)

INVZ:

$17.85M

DNA:

$183.20M

Gross Profit (TTM)

INVZ:

-$640.00K

DNA:

$120.09M

EBITDA (TTM)

INVZ:

-$67.95M

DNA:

-$338.01M

Returns By Period

In the year-to-date period, INVZ achieves a -3.57% return, which is significantly lower than DNA's 10.29% return.


INVZ

YTD

-3.57%

1M

54.29%

6M

93.55%

1Y

-8.47%

5Y*

N/A

10Y*

N/A

DNA

YTD

10.29%

1M

23.91%

6M

-3.30%

1Y

-77.62%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

INVZ vs. DNA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

INVZ
The Risk-Adjusted Performance Rank of INVZ is 4343
Overall Rank
The Sharpe Ratio Rank of INVZ is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of INVZ is 5050
Sortino Ratio Rank
The Omega Ratio Rank of INVZ is 4646
Omega Ratio Rank
The Calmar Ratio Rank of INVZ is 3939
Calmar Ratio Rank
The Martin Ratio Rank of INVZ is 4141
Martin Ratio Rank

DNA
The Risk-Adjusted Performance Rank of DNA is 1111
Overall Rank
The Sharpe Ratio Rank of DNA is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of DNA is 88
Sortino Ratio Rank
The Omega Ratio Rank of DNA is 1111
Omega Ratio Rank
The Calmar Ratio Rank of DNA is 55
Calmar Ratio Rank
The Martin Ratio Rank of DNA is 1919
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

INVZ vs. DNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Innoviz Technologies Ltd. (INVZ) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for INVZ, currently valued at -0.09, compared to the broader market-2.000.002.004.00-0.09-0.72
The chart of Sortino ratio for INVZ, currently valued at 0.67, compared to the broader market-4.00-2.000.002.004.000.67-1.16
The chart of Omega ratio for INVZ, currently valued at 1.07, compared to the broader market0.501.001.502.001.070.87
The chart of Calmar ratio for INVZ, currently valued at -0.10, compared to the broader market0.002.004.006.00-0.10-0.77
The chart of Martin ratio for INVZ, currently valued at -0.19, compared to the broader market-10.000.0010.0020.00-0.19-1.11
INVZ
DNA

The current INVZ Sharpe Ratio is -0.09, which is higher than the DNA Sharpe Ratio of -0.72. The chart below compares the historical Sharpe Ratios of INVZ and DNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.80-0.60-0.40-0.200.00AugustSeptemberOctoberNovemberDecember2025
-0.09
-0.72
INVZ
DNA

Dividends

INVZ vs. DNA - Dividend Comparison

Neither INVZ nor DNA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

INVZ vs. DNA - Drawdown Comparison

The maximum INVZ drawdown since its inception was -96.06%, roughly equal to the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for INVZ and DNA. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%-80.00%AugustSeptemberOctoberNovemberDecember2025
-85.91%
-98.19%
INVZ
DNA

Volatility

INVZ vs. DNA - Volatility Comparison

Innoviz Technologies Ltd. (INVZ) has a higher volatility of 50.18% compared to Ginkgo Bioworks Holdings, Inc. (DNA) at 33.83%. This indicates that INVZ's price experiences larger fluctuations and is considered to be riskier than DNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%AugustSeptemberOctoberNovemberDecember2025
50.18%
33.83%
INVZ
DNA

Financials

INVZ vs. DNA - Financials Comparison

This section allows you to compare key financial metrics between Innoviz Technologies Ltd. and Ginkgo Bioworks Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab